Search Results 1731-1740 of 17440 for magnesiummagnesium

1. Evaluation of the AMICUS Extracorporeal Photopheresis (ECP) System in Patients with Chronic Graft Versus Host Disease - Mayo Clinic

   Subjects who have a Total bilirubin value ≥15 mg/dL. Subjects who have veno-occlusive liver disease. Subjects who have a life expectancy < 8 weeks ...

2. A Study to Assess the Effectiveness and Safety of UGN-102 as a Primary Chemoablation Agent in Patients with Low Grade Non-Muscle-Invasive Bladder Cancer (LG NMIBC) at Intermediate Risk of Recurrence - Mayo Clinic

   ... mg/dL, Total bilirubin ≤1.5 upper limit of normal (ULN), AST (SGOT)/ALT (SGPT) ≤2.5 × upper limit of normal (ULN), ALP ≤2.5 × ULN, and Estimated ...

3. A Study of the Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) - Mayo Clinic

   About this study. The purpose of this study is to demonstrate the superiority of MD1003 (300 mg/day) over placebo to clinically improve patients with ...

4. A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) - Mayo Clinic

   * Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other ...

5. A Study to Evaluate Effectiveness of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH) - Mayo Clinic

   If receiving simvastatin-containing products: dose should not exceed 20 mg/day. Subjects must be receiving no more than three of the following previously ...

6. A Study to Evaluate the Safety and Effectiveness of the Drug TTP399 to Target A1c in Type 2 Diabetics - Mayo Clinic

   On a stable (for the last 3 months prior to screening) regimen of metformin monotherapy equivalent of at least 1000 mg once daily. Males, females of ...

7. A Study to Compare Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer - Mayo Clinic

   Patients whose serum creatinine is between 1.5 and 1.9 mg/dL are eligible if there is no hydronephrosis and the estimated creatinine clearance (CCr) is >= 30 ml ...

8. Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma - Mayo Clinic

   Able to receive concurrent prophylactic anticoagulation therapy (e.g., low-dose aspirin [81 mg] daily or an alternative prophylaxis [e.g., warfarin or low ...

9. Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) - Mayo Clinic

   ... mg/m^2 - No planned treatment with concurrent immunotherapy - Score of 1 (none) and/or 2 (a little) on the six individual European Organization for. Research ...

10. A Study to Evaluate the Pharmacokinetics of Low-Dose Bevacuzimab in Reducing Free Plasma VEGF-A in Hemodialysis Patients - Mayo Clinic

    Adequate liver function, defined as serum bilirubin ≤1.5 mg/dL; GGT, AST, ALT, and alkaline phosphatase ≤2x upper limit of normal or INR ≤ 1.5 prior to Day 0 ...